mosnodenvir (JNJ-1802) / J&J 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mosnodenvir (JNJ-1802) / J&J
NCT04906980: A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever

Terminated
2
5
RoW
JNJ-64281802, Placebo
Janssen Research & Development, LLC
Dengue
09/22
03/23
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Recruiting
2
54
US
JNJ-64281802 (sentinel high dose), JNJ-64281802 (remaining high dose), JNJ-64281802 (medium/low dose), JNJ-64281802 (daily dosing regimen X), JNJ-64281802 (weekly dosing regimen Y1), JNJ-64281802 (weekly dosing regimen Z2), Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH)
Dengue
05/23
08/24
NCT05201794: A Study of JNJ-64281802 for the Prevention of Dengue Infection

Terminated
2
1256
US, RoW
JNJ-64281802, Placebo
Janssen Research & Development, LLC
Dengue
06/24
06/24
NCT05201937: A Study of JNJ-64281802 in Healthy Adult Participants

Completed
1
33
Europe
JNJ-64281802
Janssen Research & Development, LLC
Healthy
12/22
12/22

Download Options